Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’
This article was originally published in The Pink Sheet Daily
Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.
You may also be interested in...
US House members and Center for American Progress urge policies that directly target drug pricing practices and not only patient cost sharing.
Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.